Adagene, Inc. (ADAG)
|Net Income (ttm)||-34,243|
|Trading Day||March 5|
|Day's Range||22.00 - 23.18|
|52-Week Range||20.21 - 31.83|
Adagene Inc. Announces Closing of Initial Public Offering and Exercise of Underwriters' Over-Allotment Option
SAN FRANCISCO, Feb. 11, 2021 (GLOBE NEWSWIRE) -- Adagene Inc. ("Adagene" or the "Company") (Nasdaq: ADAG), a platform-driven, clinical-stage biopharmaceutical company committed to transforming...
SAN FRANCISCO, Calif., Feb. 09, 2021 (GLOBE NEWSWIRE) -- Adagene Inc. ("Adagene" or the "Company") (Nasdaq: ADAG), a platform-driven, clinical-stage biopharmaceutical company committed to tran...
Exelixis and Adagene Enter into Collaboration and License Agreement to Develop Novel Masked Antibody-Drug Conjugate Therapies with Improved Safety and Efficacy Profiles
Exelixis, Inc. (Nasdaq: EXEL) and Adagene today announced a collaboration and license agreement under which Exelixis will utilize Adagene’s SAFEbody™ technology platform...
Adagene, a Phase 1 biotech developing antibody cancer immunotherapies in China, filed on Tuesday with the SEC to raise up to $125 million in an initial public offering.
Adagene, Inc. has filed to go public with an IPO on the NASDAQ.
News briefing: AbbVie selects first target for Dragonfly partnership; Cognito nets BDD for Alzheimer's treatment device
Dragonfly’s partnership with AbbVie is beginning to bear fruit. AbbVie has selected its first NK cell engager-based immunotherapy as part of the deal, triggering an undisclosed opt-in payment,...
Yields potential first-ever antibodies targeting human endogenous retrovirus associated with kidney cancer.
Adagene, a clinical stage biopharmaceutical company, engages in the research, development, and production of monoclonal antibody drugs for cancers. Its products include ADG106, a human ligand-blocking agonistic anti-CD137 monoclonal antibodies (mAbs) that is in Phase Ib clinical trials for the treatment advanced solid tumors and non-Hodgkin's lymphoma; ADG126, a fully-human anti-CTLA-4 mAb that is in preclinical stage used in the treatment of cancers; and ADG116, a human ligand-blocking anti-CTLA-4 mAb, which is in Phase I clinical trial for th... [Read more...]
|IPO Date |
Feb 9, 2021
Peter (Peizhi) Luo, Ph.D.
|Stock Exchange |
|Ticker Symbol |
In 2019, Adagene's revenue was $480,000, a decrease of -68.24% compared to the previous year's $1.51 million. Losses were -$16.43 million, 7.64% more than in 2018.